We had the pleasure of welcoming and hearing from our new CEO, Christian Tucat, during several town halls held in our UK offices last week. By way of a very interactive Q&A session, Christian candidly shared his insights, business vision and priorities for the months ahead, whilst meeting and greeting the hundreds of colleagues who attended the town halls. Christian also toured Sciensus’ facilities across the country and was given a comprehensive overview of the business and services we provide. It’s an exciting new chapter for Sciensus as we officially welcome Christian to the team
We are proud to announce that Sciensus has earned the prestigious National Equality Standard (NES) accreditation! This is a significant milestone in our journey to becoming a leader in Equality, Diversity, and Inclusion (EDI). At Sciensus, diversity is a core value and one that drives innovation and excellence in everything we do. Sciensus’ NES accreditation highlights our ongoing commitment to building a working environment where everyone can thrive and do their best work regardless of background. To learn more about what this accreditation means for us, Please follow the link
Explore Your Recruitment Journey with Us! 🌟 Curious about what joining our team looks like? Check out our recruitment journey guide to see each step of our hiring process and how we support you along the way. Whether you're just starting to explore opportunities or preparing for an interview, this guide covers what to expect. Dive in to learn more and get ready for an exciting journey with us!
Sciensus names Christian Tucat as Chief Executive Officer Mr Tucat brings 25 years of experience in the life sciences sector, primarily focusing on helping pharmaceutical companies deliver lifesaving drugs and therapies to patients. Prior to joining Sciensus, Mr Tucat held multiple senior roles at Syneos Health, including Chief Business Officer, President of Syneos One and President of Real-World Evidence Solutions. His career also includes leadership positions at INC Research, PRA International, Eli Lilly, and GlaxoSmithKline.
